Think of it as radical bio-intelligence
We combine artificial intelligence with automation to conduct experimental biology at scale — testing thousands of compounds on hundreds of cellular disease models in parallel. Our embrace of systems biology and our commitment to an unbiased approach are leading to novel discoveries. With every experiment, our system gets smarter.
We’re aiming for 100 new treatments by 2025
We know this sounds improbable, but we wanted ambitious goals to stretch ourselves further, force ourselves to question assumptions, and move faster. The results in our pipeline indicate we are onto something. Look at the data with us.
“Deep learning has recently proven capable of driving cars, beating the world champion of the game of Go, translating from one language to another and recognizing faces dramatically better than any previous efforts to date. Recursion is taking this success and applying it to millions of high-resolution cellular images, with a high potential to make biological discoveries with a medical impact and breadth never seen before.”
Recursion Scientific Advisor
Our investors
The latest news
Articles and Press Releases
05.15.18
Medicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals
Former Pfizer and Eli Lilly chemists join Recursion
05.07.18
Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease
The grant will accelerate the discovery of treatments for malaria
05.01.18
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Dr. Lynch joins Recursion during a rapid expansion in the company’s drug discovery efforts
